List of the transcripts differentially expressed in ATRA-resistant acute promyelocytic leukemia cells treated with the CHK1 inhibitor MK-8776, compared to untreated cells (Franza et al., 2023)

The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia (APL) cells. Here we show the list of the 1055 transcripts that were found significantly differentially expressed in MK-8776-treated APL cells compared to untreated ones (FDR≤0.05; Benjamini–Hochberg correction). RNA samples have been amplified, fragmented, and labeled for array hybridization according to the manufacturer’s instruction. Samples were then hybridized ON, washed, stained, and scanned using the Affymetrix GeneChip Hybridization Oven 640, Fluidic Station 450 and Scanner 3000 7G (Thermo Fisher Scientific) to generate the raw data files.